Sartorius extends process development offering with Cellca acquisition

Cellca — based in Laupheim, Germany, and catering for biopharmaceutical companies and biosimilar firms that do not or only partly conduct their cell line and process development in-house — has been acquired by Sartorius Stedim Biotech.

Founded in 2005 and with around 30 employees, Cellca generated sales revenue of approximately €6 million in 2014. Following hot on the heels of SSB's acquisitions of BioOutsource and TAP Biosystems, the company is reaffirming its commitment to expanding its process development services offering. 

Reinhard Vogt, member of the SSB Executive Committee for Marketing and Sales, commented: “Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics."

Hugo de Wit, managing director of Cellca, added: “Due to its global presence and high reputation, Sartorius Stedim Biotech is an ideal partner for Cellca. We now have a strong base to further expand and develop our business internationally."